References
- American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p 491–6.
- Higaki I, Hirohashi K, Fukushima S, Wanibuchi H, Seike N, Yamane T, Renal pelvic carcinoma producing granulocyte colony-stimulating factor: report of a case. Surg Today 2001;31:266–8.
- Terao S, Yamada Y, Shirakawa T, Hara I, Kanomata N, Kamidono S. Granulocyte-colony stimulating factor producing urothelial carcinoma of renal pelvis. Int J Urol 2005;12:500–2.
- Turalic H, Deamant FD, Reese JH. Paraneoplastic production of granulocyte colony-stimulating factor in a bladder carcinoma. Scand J Urol Nephrol 2006;40:429–32.
- Tachibana M, Miyakawa A, Tazaki H, Nakamura K, Kubo A, Hata J, Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. Cancer Res 1995;55:3438–43.
- Chakraborty A, Guha S. Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells. Urology 2007;69:1210–15.
- Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010;39:493–506.
- Aziz MH, Hafeez BB, Sand JM, Pierce DB, Aziz SW, Dreckschmidt NE, Protein kinase Cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene 2010;29:3100–9.
- Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 2009;106:6742–7.
- Schlahsa L, Jaimes Y, Blasczyk R, Figueiredo C. Granulocyte-colony-stimulatory factor: a strong inhibitor of natural killer cell function. Transfusion 2011;51:293–305.